Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Biotechnology

Healthcare
$127.16 +1.54%

+$1.72 today

Market cap
$8.30B
Beta
1.83
P/E (TTM)
-64.2
EPS (TTM)
-$1.76
52W Low $49.38High $114.00

Volume 0.43M

Average 0.72M

PTGX Pre-Tax Margin

Income before tax as a percentage of revenue.

Protagonist Therapeutics, Inc.NASDAQ: PTGX

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin widens to 77.3%

Pre-tax margin was 77.3% in Q2 FY2026, up 701.2 pp from a year earlier. On a trailing-twelve-month basis it was 29.9%, up 4.2 pp year over year. Over 3 fiscal years it widened by 198.3 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
77.3%+73.3 pp QoQ
Last fiscal yearDec 2025
-281.0%-345.3 pp YoY
LTMJun 2026
29.9%+4.2 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+701.2 pp——
1 year-345.3 pp——
3 years+198.3 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-281.0%
Year-over-year change
-345.3pp

Pre-Tax Margin vs competitors

How PTGX compares with its peers on the latest reported figures

  • PTGX's LTM Jun 2026 pre-tax margin of 29.9% is the highest of the 5 companies compared; the peer median is -562.1%.
  • Its year-over-year change of +4.2 pp is the 2nd highest of 3, against a peer median of +7.0 pp.
  • Over three fiscal years its change of +198.3 pp compares with a peer median of +354.0 pp.
PTGX Competitors Peer median
Pre-Tax Margin for PTGX and competitors
Company Period LTM level YoY 3-year change
PTGXProtagonist Therapeutics, Inc.LTM Jun 202629.9% +4.2 pp+198.3 pp
ANABAnaptysBio, Inc.LTM Mar 2026-11.5% +114.2 pp+1245.5 pp
SYRESpyre Therapeutics, Inc.LTM Sep 2026-291.6% ——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-832.6% -100.2 pp-537.5 pp
IMVTImmunovant, Inc.LTM Sep 2026-7191.7% ——
IRONDisc Medicine, Inc.FY2025— ——
ODTXOdyssey Therapeutics, Inc.—— ——
IMUXImmunic, Inc.FY2025— ——
Peer median (excluding PTGX) -562.1%+7.0 pp+354.0 pp

Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.36M26.58M60M434.43M46.02M
Cost of Revenue00001.23M
Gross Profit27.36M26.58M60M434.43M44.79M
Gross Margin100.0%100.0%100.0%100.0%97.3%
Research & Development126.01M126.22M120.16M138.13M159.29M
Selling, General & Admin27.2M31.74M33.49M43.46M44.85M
Operating Expenses153.2M157.95M153.65M181.59M202.92M
Depreciation & Amortization2.78M3.37M3.31M2.96M1.28M
EBITDA(122.78M)(124.02M)(75.64M)282.37M(128.03M)
EBITDA Margin-448.8%-466.6%-126.1%65.0%-278.2%
Operating Income(125.85M)(131.37M)(93.65M)252.84M(158.13M)
Operating Margin-460.0%-494.2%-156.1%58.2%-343.6%
Interest Income443K4.06M14.9M26.32M28.79M
Interest Expense00000
Other Income / Expenses294K3.98M14.7M26.57M28.82M
Income Before Tax(125.55M)(127.39M)(78.96M)279.41M(129.31M)
Pre-Tax Margin-458.9%-479.3%-131.6%64.3%-281.0%
Income Tax Expense0004.22M838K
Net Income(125.55M)(127.39M)(78.96M)275.19M(130.15M)
Net Margin-458.9%-479.3%-131.6%63.3%-282.8%
EPS (Basic)(2.65)(2.52)(1.39)4.47(2.05)
EPS (Diluted)(2.65)(2.52)(1.39)4.23(2.05)
Weighted Avg Shares46.32M49.04M56.76M61.57M63.57M
Weighted Avg Shares (Diluted)46.32M49.04M56.76M65.08M63.57M

Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Intrinsic Alpha fair value

Locked

Current Price

$127.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.